PEMF Therapy Boosts Muscle Strength 42% and Cuts Depression in Sarcopenic Elders

Sarcopenia — the age-related loss of muscle mass and strength — affects 10–16% of community-dwelling older adults and up to 76% of hospitalized patients, driving falls, fractures, early institutionalization, and rising healthcare costs. While resistance training remains the gold-standard treatment, many frail elderly individuals cannot adhere due to joint pain, comorbidities, or logistical barriers. This study investigated whether pulsed electromagnetic field (PEMF) therapy — a passive, load-free neuromuscular stimulation modality — could serve as a viable alternative for this population.

The trial enrolled 25 older adults (10 men, 15 women; mean age ≥65) with confirmed sarcopenia based on SARC-F + calf circumference screening and impaired TUG performance per EWGSOP2 criteria. A separate control group of 16 older adults was assessed at baseline only, serving as a reference for ANCOVA adjustment. The PEMF protocol consisted of 12 sessions over four weeks (three per week, 30 minutes each), targeting the quadriceps via flat handles and the gastrocnemius via concave handles. Intensity progressed from 10–20% (0.75–1.5 Teslas) during two adaptation sessions to 40–70% (3.0–5.2 Teslas) across the remaining 10 sessions, with frequencies cycling between 5 Hz submaximal and 30 Hz tetanic contractions.

The primary outcome — knee extensor strength measured by computerized dynamometry — improved from 13.05 ± 4.8 kgf to 18.56 ± 8.0 kgf (p < 0.001), representing a 42% relative increase. Functional mobility on the Timed Up and Go test improved from 23.1 ± 14.4 seconds to 18.7 ± 10.0 seconds (p = 0.048), a clinically meaningful reduction given that TUG times above 12–14 seconds are associated with fall risk. These gains are particularly notable given the short four-week intervention window.

Secondary outcomes showed a significant reduction in Yesavage Geriatric Depression Scale scores from 7.9 ± 2.4 to 5.4 ± 1.7 (p = 0.0013), suggesting that PEMF-induced improvements in physical function may carry psychological benefits — or that the electromagnetic stimulation itself has neurological effects. SARC-F + CC composite scores decreased from 11.6 ± 8.2 to 6.5 ± 7.6 (p < 0.001), though the group-by-time interaction was not statistically significant (p = 0.252). Calf circumference showed a non-significant increase from 34.0 to 36.0 cm (p = 0.548), suggesting that four weeks is insufficient to produce measurable hypertrophy.

The proposed mechanism involves PEMF-induced depolarization of motor neurons independent of central command, triggering calcium influx and muscle contractions that mimic resistance training adaptations at the neuromuscular level. The authors suggest this pathway may explain strength gains without corresponding changes in muscle mass — a neural adaptation pattern consistent with early-phase resistance training responses. Clinically, PEMF represents a passive, well-tolerated intervention that could be deployed in clinical or home settings for patients unable to exercise conventionally. However, the non-randomized design, single-arm intervention, and baseline-only control group limit causal inference, and larger randomized trials with longer follow-up and imaging-confirmed muscle mass outcomes are needed.